Titre : Interleukine-27

Interleukine-27 : Questions médicales fréquentes

Termes MeSH sélectionnés :

Attention Deficit Disorder with Hyperactivity
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Interleukine-27 : Questions médicales les plus fréquentes", "headline": "Interleukine-27 : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Interleukine-27 : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-02-24", "dateModified": "2025-02-18", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Interleukine-27" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Interleukines", "url": "https://questionsmedicales.fr/mesh/D007378", "about": { "@type": "MedicalCondition", "name": "Interleukines", "code": { "@type": "MedicalCode", "code": "D007378", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D23.529.374.465" } } }, "about": { "@type": "MedicalCondition", "name": "Interleukine-27", "alternateName": "Interleukin-27", "code": { "@type": "MedicalCode", "code": "D064094", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Cory M Robinson", "url": "https://questionsmedicales.fr/author/Cory%20M%20Robinson", "affiliation": { "@type": "Organization", "name": "Department of Microbiology, Immunology, & Cell Biology, West Virginia University School of Medicine, Morgantown, WV, United States." } }, { "@type": "Person", "name": "Tomozumi Imamichi", "url": "https://questionsmedicales.fr/author/Tomozumi%20Imamichi", "affiliation": { "@type": "Organization", "name": "Laboratory of Human Retrovirology and Immunoinformatics, Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA." } }, { "@type": "Person", "name": "Jessica M Povroznik", "url": "https://questionsmedicales.fr/author/Jessica%20M%20Povroznik", "affiliation": { "@type": "Organization", "name": "Department of Microbiology, Immunology, & Cell Biology, West Virginia University School of Medicine, Morgantown, WV, United States." } }, { "@type": "Person", "name": "Jordan K Vance", "url": "https://questionsmedicales.fr/author/Jordan%20K%20Vance", "affiliation": { "@type": "Organization", "name": "Department of Microbiology, Immunology, & Cell Biology, West Virginia University School of Medicine, Morgantown, WV, United States." } }, { "@type": "Person", "name": "Xiaojun Hu", "url": "https://questionsmedicales.fr/author/Xiaojun%20Hu", "affiliation": { "@type": "Organization", "name": "Laboratory of Human Retrovirology and Immunoinformatics, Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "The perceived quality of maternal care during childhood shapes attentional bias to infant faces in parents and nonparents.", "datePublished": "2024-03-21", "url": "https://questionsmedicales.fr/article/38512216", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1037/fam0001198" } }, { "@type": "ScholarlyArticle", "name": "DuKA: A Dual-Keyless-Attention Model for Multi-Modality EHR Data Fusion and Organ Failure Prediction.", "datePublished": "2024-03-20", "url": "https://questionsmedicales.fr/article/38039165", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1109/TBME.2023.3331305" } }, { "@type": "ScholarlyArticle", "name": "STADNet: Spatial-Temporal Attention-Guided Dual-Path Network for cardiac cine MRI super-resolution.", "datePublished": "2024-03-12", "url": "https://questionsmedicales.fr/article/38492252", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.media.2024.103142" } }, { "@type": "ScholarlyArticle", "name": "iPro2L-DG: Hybrid network based on improved densenet and global attention mechanism for identifying promoter sequences.", "datePublished": "2024-03-06", "url": "https://questionsmedicales.fr/article/38510021", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.heliyon.2024.e27364" } }, { "@type": "ScholarlyArticle", "name": "Less common phenotypes of myelin oligodendrocyte glycoprotein antibody-related diseases in children deserve more attention.", "datePublished": "2024-03-04", "url": "https://questionsmedicales.fr/article/38438553", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1038/s41390-024-03058-x" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Facteurs biologiques", "item": "https://questionsmedicales.fr/mesh/D001685" }, { "@type": "ListItem", "position": 3, "name": "Protéines et peptides de signalisation intercellulaire", "item": "https://questionsmedicales.fr/mesh/D036341" }, { "@type": "ListItem", "position": 4, "name": "Cytokines", "item": "https://questionsmedicales.fr/mesh/D016207" }, { "@type": "ListItem", "position": 5, "name": "Interleukines", "item": "https://questionsmedicales.fr/mesh/D007378" }, { "@type": "ListItem", "position": 6, "name": "Interleukine-27", "item": "https://questionsmedicales.fr/mesh/D064094" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Interleukine-27 - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Interleukine-27", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-18", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Interleukine-27", "description": "Comment mesurer l'IL-27 dans le sang ?\nQuels tests sont utilisés pour évaluer l'IL-27 ?\nL'IL-27 est-elle mesurée dans des maladies spécifiques ?\nQuels biomarqueurs sont associés à l'IL-27 ?\nL'IL-27 peut-elle être un indicateur de gravité ?", "url": "https://questionsmedicales.fr/mesh/D064094?mesh_terms=Attention+Deficit+Disorder+with+Hyperactivity&page=998#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Interleukine-27", "description": "Quels symptômes sont liés à une élévation de l'IL-27 ?\nL'IL-27 est-elle liée à des douleurs articulaires ?\nQuels signes cliniques sont associés à l'IL-27 ?\nL'IL-27 influence-t-elle les symptômes respiratoires ?\nY a-t-il des symptômes neurologiques liés à l'IL-27 ?", "url": "https://questionsmedicales.fr/mesh/D064094?mesh_terms=Attention+Deficit+Disorder+with+Hyperactivity&page=998#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Interleukine-27", "description": "Peut-on prévenir l'élévation de l'IL-27 ?\nY a-t-il des vaccins liés à l'IL-27 ?\nComment l'alimentation influence-t-elle l'IL-27 ?\nL'exercice physique affecte-t-il l'IL-27 ?\nLe sommeil influence-t-il l'IL-27 ?", "url": "https://questionsmedicales.fr/mesh/D064094?mesh_terms=Attention+Deficit+Disorder+with+Hyperactivity&page=998#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Interleukine-27", "description": "Quels traitements ciblent l'IL-27 ?\nL'IL-27 peut-elle être inhibée ?\nQuels médicaments affectent l'IL-27 ?\nL'IL-27 est-elle une cible pour l'immunothérapie ?\nComment l'IL-27 influence-t-elle les traitements ?", "url": "https://questionsmedicales.fr/mesh/D064094?mesh_terms=Attention+Deficit+Disorder+with+Hyperactivity&page=998#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Interleukine-27", "description": "Quelles complications sont liées à l'IL-27 ?\nL'IL-27 est-elle impliquée dans des maladies chroniques ?\nComment l'IL-27 affecte-t-elle le cancer ?\nY a-t-il des risques d'infection liés à l'IL-27 ?\nL'IL-27 est-elle liée à des troubles neurologiques ?", "url": "https://questionsmedicales.fr/mesh/D064094?mesh_terms=Attention+Deficit+Disorder+with+Hyperactivity&page=998#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Interleukine-27", "description": "Quels facteurs augmentent l'IL-27 ?\nL'âge influence-t-il les niveaux d'IL-27 ?\nLes maladies auto-immunes sont-elles un facteur de risque ?\nLe tabagisme affecte-t-il l'IL-27 ?\nY a-t-il un lien entre l'IL-27 et l'alimentation ?", "url": "https://questionsmedicales.fr/mesh/D064094?mesh_terms=Attention+Deficit+Disorder+with+Hyperactivity&page=998#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment mesurer l'IL-27 dans le sang ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "L'IL-27 peut être mesurée par des tests ELISA dans des échantillons de sérum." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour évaluer l'IL-27 ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des tests immunologiques comme l'ELISA et la cytométrie en flux sont utilisés." } }, { "@type": "Question", "name": "L'IL-27 est-elle mesurée dans des maladies spécifiques ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'IL-27 est souvent mesurée dans des maladies auto-immunes et inflammatoires." } }, { "@type": "Question", "name": "Quels biomarqueurs sont associés à l'IL-27 ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "L'IL-27 est souvent associée à d'autres cytokines comme l'IL-6 et l'IL-10." } }, { "@type": "Question", "name": "L'IL-27 peut-elle être un indicateur de gravité ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des niveaux élevés d'IL-27 peuvent indiquer une inflammation sévère." } }, { "@type": "Question", "name": "Quels symptômes sont liés à une élévation de l'IL-27 ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Une élévation de l'IL-27 peut entraîner des symptômes d'inflammation comme la fièvre." } }, { "@type": "Question", "name": "L'IL-27 est-elle liée à des douleurs articulaires ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'IL-27 peut contribuer à des douleurs articulaires dans les maladies inflammatoires." } }, { "@type": "Question", "name": "Quels signes cliniques sont associés à l'IL-27 ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Les signes cliniques incluent fatigue, douleurs et symptômes systémiques d'inflammation." } }, { "@type": "Question", "name": "L'IL-27 influence-t-elle les symptômes respiratoires ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'IL-27 peut exacerber les symptômes respiratoires dans certaines maladies pulmonaires." } }, { "@type": "Question", "name": "Y a-t-il des symptômes neurologiques liés à l'IL-27 ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Des niveaux élevés d'IL-27 peuvent être associés à des symptômes neurologiques dans certaines conditions." } }, { "@type": "Question", "name": "Peut-on prévenir l'élévation de l'IL-27 ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Des modes de vie sains et une gestion du stress peuvent aider à prévenir l'élévation de l'IL-27." } }, { "@type": "Question", "name": "Y a-t-il des vaccins liés à l'IL-27 ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Actuellement, il n'existe pas de vaccins spécifiquement ciblant l'IL-27." } }, { "@type": "Question", "name": "Comment l'alimentation influence-t-elle l'IL-27 ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Une alimentation anti-inflammatoire peut aider à réguler les niveaux d'IL-27." } }, { "@type": "Question", "name": "L'exercice physique affecte-t-il l'IL-27 ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'exercice régulier peut réduire les niveaux d'IL-27 et améliorer la santé immunitaire." } }, { "@type": "Question", "name": "Le sommeil influence-t-il l'IL-27 ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Un sommeil adéquat est crucial pour maintenir des niveaux sains d'IL-27 et une bonne santé." } }, { "@type": "Question", "name": "Quels traitements ciblent l'IL-27 ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Des thérapies biologiques ciblant l'IL-27 sont en développement pour les maladies auto-immunes." } }, { "@type": "Question", "name": "L'IL-27 peut-elle être inhibée ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des inhibiteurs spécifiques de l'IL-27 sont à l'étude pour réduire l'inflammation." } }, { "@type": "Question", "name": "Quels médicaments affectent l'IL-27 ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Certains médicaments anti-inflammatoires peuvent moduler les niveaux d'IL-27." } }, { "@type": "Question", "name": "L'IL-27 est-elle une cible pour l'immunothérapie ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'IL-27 est une cible potentielle pour l'immunothérapie dans le cancer." } }, { "@type": "Question", "name": "Comment l'IL-27 influence-t-elle les traitements ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "L'IL-27 peut influencer l'efficacité des traitements en modulant la réponse immunitaire." } }, { "@type": "Question", "name": "Quelles complications sont liées à l'IL-27 ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Des niveaux élevés d'IL-27 peuvent entraîner des complications dans les maladies auto-immunes." } }, { "@type": "Question", "name": "L'IL-27 est-elle impliquée dans des maladies chroniques ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'IL-27 est associée à des maladies chroniques comme l'arthrite et le lupus." } }, { "@type": "Question", "name": "Comment l'IL-27 affecte-t-elle le cancer ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "L'IL-27 peut avoir un rôle double dans le cancer, favorisant ou inhibant la croissance tumorale." } }, { "@type": "Question", "name": "Y a-t-il des risques d'infection liés à l'IL-27 ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Des niveaux élevés d'IL-27 peuvent augmenter le risque d'infections en modulant l'immunité." } }, { "@type": "Question", "name": "L'IL-27 est-elle liée à des troubles neurologiques ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des niveaux anormaux d'IL-27 peuvent être associés à des troubles neurologiques comme la sclérose en plaques." } }, { "@type": "Question", "name": "Quels facteurs augmentent l'IL-27 ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Le stress, l'obésité et les infections chroniques peuvent augmenter les niveaux d'IL-27." } }, { "@type": "Question", "name": "L'âge influence-t-il les niveaux d'IL-27 ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les niveaux d'IL-27 peuvent augmenter avec l'âge, affectant la réponse immunitaire." } }, { "@type": "Question", "name": "Les maladies auto-immunes sont-elles un facteur de risque ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les personnes atteintes de maladies auto-immunes présentent souvent des niveaux élevés d'IL-27." } }, { "@type": "Question", "name": "Le tabagisme affecte-t-il l'IL-27 ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le tabagisme peut augmenter les niveaux d'IL-27 et aggraver l'inflammation." } }, { "@type": "Question", "name": "Y a-t-il un lien entre l'IL-27 et l'alimentation ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Certaines habitudes alimentaires peuvent influencer les niveaux d'IL-27, notamment les régimes riches en sucres." } } ] } ] }

Sources (10000 au total)

DuKA: A Dual-Keyless-Attention Model for Multi-Modality EHR Data Fusion and Organ Failure Prediction.

Organ failure is a leading cause of mortality in hospitals, particularly in intensive care units. Predicting organ failure is crucial for clinical and social reasons. This study proposes a dual-keyles... Three modalities of medical data from EHR, namely diagnosis, procedure, and medications, are selected to predict three types of vital organ failures: heart failure, respiratory failure, and kidney fai... The proposed multi-modality DuKA model outperforms all reference and baseline models. The diagnosis history, particularly the presence of cachexia and previous organ failure, emerges as the most influ... DuKA offers competitive performance, straightforward model interpretations and flexibility in terms of input sources, as the input embeddings can be trained using different datasets and methods.... DuKA is a lightweight model that innovatively uses dual attention in a hierarchical way to fuse diagnosis, procedure and medication information for organ failure predictions. It also enhances disease ...

Less common phenotypes of myelin oligodendrocyte glycoprotein antibody-related diseases in children deserve more attention.

To facilitate the identification of less common clinical phenotypes of myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in children.... We retrospectively reviewed medical records of 236 patients with MOGAD. The following phenotypes were considered to be typical for MOGAD: ADEM, ON, TM, and NMOSD. Less common onset clinical phenotypes... 16 cases (6.8%) presented as cortical encephalitis, with convulsions, headache, and fever as the main symptoms. 15 cases were misdiagnosed in the early period. 13 cases (5.5%) showed the overlapping s... 40/236 (16.9%) of children with MOGAD had less common phenotypes. Less common clinical phenotypes of pediatric MOGAD are susceptible to misdiagnosis and deserve more attention.... This is the first comprehensive analysis and summary of all less commonl clinical phenotypes of MOGAD in children, while previous studies have only focused on a specific phenotype or case reports. We ...

No effects of the theta-frequency transcranial electrical stimulation for recall, attention control, and relation integration in working memory.

Recent studies have suggested that transcranial alternating current stimulation (tACS), and especially the theta-frequency tACS, can improve human performance on working memory tasks. However, evidenc... In a relatively large sample of young healthy participants (... For each task administered, we observed significant gains in accuracy neither for the frontal tACS session nor for the parietal tACS session, as compared to the sham session. By contrast, the scores o... The results suggest that canonical measures of WM capacity are strongly stable in time and hardly affected by theta-frequency tACS. Either the tACS effects observed in the n-back and change detection ...